BACKGROUND: Specialized clinical care for cystic fibrosis (CF) in Cyprus, a small island country, has been implemented since the 1990s. However, only recently, a national CF patient registry has been established for the systematic recording of patients' data. In this study, we aim to present data on the epidemiological, genotypic and phenotypic features of CF patients in the country from the most recent data collection in 2019, with particular emphasis on notable rare or unique cases. RESULTS: Overall, data from 52 patients are presented, 5 of whom have deceased and 13 have been lost to follow-up in previous years. The mean age at diagnosis was 7.2 ± 12.3 years, and the mean age of 34 alive patients by the end of 2019 was 22.6 ± 13.2 years. Patients most commonly presented at diagnosis with acute or persistent respiratory symptoms (46.2%), failure to thrive or malnutrition (40.4%), and dehydration or electrolyte imbalance (32.7%). Sweat chloride levels were diagnostic (above 60 mmol/L) in 81.8% of examined patients. The most common identified mutation was p.Phe508del (F508del) (45.2%), followed by p.Leu346Pro (L346P) (6.7%), a mutation detected solely in individuals of Cypriot descent. The mean BMI and FEV1 z-scores were 0.2 ± 1.3 and - 2.1 ± 1.7 across all age groups, respectively, whereas chronic Pseudomonas aeruginosa colonization was noted in 26.9% of patients. The majority of patients (74.5%) were eligible to receive at least one of the available CFTR modulator therapies. In 25% of patients we recovered rare or unique genotypic profiles, including the endemic p.Leu346Pro (L346P), the rare CFTR-dup2, the co-segregated c.4200_4201delTG/c.489 + 3A > G, and the polymorphism p.Ser877Ala. CONCLUSIONS: CF patient registries are particularly important in small or isolated populations, such as in Cyprus, with rare or unique disease cases. Their operation is necessary for the optimization of clinical care provided to CF patients, enabling their majority to benefit from evolving advances in precision medicine.

Cyprus School of Molecular Medicine The Cyprus Institute of Neurology and Genetics Nicosia Cyprus

Department of Biology and Medical Genetics 2nd Faculty of Medicine and Motol University Hospital Charles University Prague Czechia

Department of Clinical Genetics The Cyprus Institute of Neurology and Genetics Nicosia Cyprus

Department of Molecular Genetics Function and Therapy The Cyprus Institute of Neurology and Genetics Nicosia Cyprus

Paediatric Pulmonology Unit Hospital 'Archbishop Makarios III' Nicosia Cyprus

Private Practice Nicosia Cyprus

Pulmonology Clinic Nicosia General Hospital Nicosia Cyprus

Pulmonology Clinic Paphos General Hospital Paphos Cyprus

Respiratory Physiology Laboratory Medical School Shacolas Educational Centre for Clinical Medicine University of Cyprus 215 6 Palaios Dromos Lefkosias Lemesou 2029 Aglantzia Nicosia Cyprus

See more in PubMed

Schechter MS, Fink AK, Homa K, Goss CH. The Cystic Fibrosis Foundation Patient Registry as a tool for use in quality improvement. BMJ Qual Saf. 2014;23(Suppl 1):i9–14. PubMed

Fink AK, Loeffler DR, Marshall BC, Goss CH, Morgan WJ. Data that empower: the success and promise of CF patient registries. Pediatr Pulmonol. 2017;52(S48):S44–S51. PubMed

Dasenbrook EC, Sawicki GS. Cystic fibrosis patient registries: a valuable source for clinical research. J Cyst Fibros. 2018;17(4):433–440. PubMed

Jackson AD, Goss CH. Epidemiology of CF: how registries can be used to advance our understanding of the CF population. J Cyst Fibros. 2018;17(3):297–305. PubMed

Yiallouros PK, Neocleous V, Zeniou M, Adamidou T, Costi C, Christophi C, Tzetis M, Kanavakis E, Deltas C. Cystic fibrosis mutational spectrum and genotypic/phenotypic features in Greek-Cypriots, with emphasis on dehydration as presenting symptom. Clin Genet. 2007;71(3):290–292. PubMed

Bobadilla JL, Macek M, Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations—correlation with incidence data and application to screening. Hum Mutat. 2002;19(6):575–606. PubMed

Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. J Pediatr. 1998;132(4):589–595. PubMed

Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics. 1959;23(3):545–549. PubMed

Boteva K, Papageorgiou E, Georgiou C, Angastiniotis M, Middleton LT, Constantinou-Deltas CD. Novel cystic fibrosis mutation associated with mild disease in Cypriot patients. Hum Genet. 1994;93(5):529–532. PubMed

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA. Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220–231. PubMed PMC

Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E. VX-445–tezacaftor–ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med. 2018;379(17):1612–1620. PubMed PMC

Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F. Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809–1819. PubMed PMC

Davies JC, Sermet-Gaudelus I, Naehrlich L, Harris RS, Campbell D, Ahluwalia N, Short C, Haseltine E, Panorchan P, Saunders C. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation. J Cyst Fibros. 2021;20(1):68–77. PubMed

Forzan M, Salviati L, Pertegato V, Casarin A, Bruson A, Trevisson E, Di Gianantonio E, Clementi M. Is CFTR 621 3 A> G a cystic fibrosis causing mutation? J Hum Genet. 2010;55(1):23–26. PubMed

Harrison SM, Biesecker LG, Rehm HL. Overview of specifications to the ACMG/AMP variant interpretation guidelines. Curr Protoc Hum Genet. 2019;103(1):e93. PubMed PMC

Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M, Wilschanski M. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros. 2011;10:S86–S102. PubMed

Zolin A, McKone E, Van Rens J, Fox A, Iansa P, Preftitsi A. ECFSPR annual report 2017. European Cystic Fibrosis Society; 2016.

Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–1672. PubMed PMC

Neocleous V, Yiallouros PK, Tanteles GA, Costi C, Moutafi M, Ioannou P, Patsalis PC, Sismani C, Phylactou LA. Apparent Homozygosity of p. Phe508del in CFTR due to a Large Gene Deletion of Exons 4–11. Case reports in genetics 2014; 2014. PubMed PMC

Dogru D, Çakır E, Şişmanlar T, Çobanoğlu N, Pekcan S, Cinel G, Yalçın E, Kiper N, Şen V, Şen H. Cystic fibrosis in Turkey: first data from the national registry. Pediatr Pulmonol. 2020;55(2):541–548. PubMed

Yalçin E, Kiper N, Doğru D, Özçelik U, Aslan AT. Clinical features and treatment approaches in cystic fibrosis with pseudo-Bartter syndrome. Ann Trop Paediatr. 2005;25(2):119–124. PubMed

Dahabreh MM, Najada AS. Pseudo-bartter syndrome, pattern and correlation with other cystic fibrosis features. Saudi J Kidney Dis Transpl. 2013;24(2):292–296. PubMed

Al-Mobaireek KF, Abdullah AMA. Cystic fibrosis in Saudi Arabia: common and rare presentations. Ann Trop Paediatr. 1995;15(4):269–272. PubMed

Camajova J, Berwouts S, Matthijs G, Macek M, Dequeker E. Variability in the use of CE-marked assays for in vitro diagnostics of CFTR gene mutations in European genetic testing laboratories. Eur J Hum Genet. 2009;17(4):537–540. PubMed PMC

Mall MA, Galietta LJ. Targeting ion channels in cystic fibrosis. J Cyst Fibros. 2015;14(5):561–570. PubMed

Mall MA. ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies. Eur Respir J. 2020 doi: 10.1183/13993003.00946-2020. PubMed DOI PMC

Girodon E, Cazeneuve C, Lebargy F, Chinet T, Costes B, Ghanem N, Martin J, Lemay S, Scheid P, Housset B. CFTR gene mutations in adults with disseminated bronchiectasis. Eur J Hum Genet. 1997;5:149–155. PubMed

Wang X, Moylan B, Leopold DA, Kim J, Rubenstein RC, Togias A, Proud D, Zeitlin PL, Cutting GR. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA. 2000;284(14):1814–1819. PubMed

Boyle MP. Nonclassic cystic fibrosis and CFTR-related diseases. Curr Opin Pulm Med. 2003;9(6):498–503. PubMed

Reyes A, Cruickshank T, Ziman M, Nosaka K. Pulmonary function in patients with Huntington’s disease. BMC Pulm Med. 2014;14(1):1–8. PubMed PMC

Loumi O, Ferec C, Mercier B, Creff J, Fercot B, Denine R, Grangaud J. CFTR mutations in the Algerian population. J Cyst Fibros. 2008;7(1):54–59. PubMed

Tzetis M, Efthymiadou A, Doudounakis S, Kanavakis E. Qualitative and quantitative analysis of mRNA associated with four putative splicing mutations (621 3A→ G, 2751 2T→ A, 296 1G→ C, 1717–9T→ C-D565G) and one nonsense mutation (E822X) in the CFTR gene. Hum Genet. 2001;109(6):592–601. PubMed

Tomaiuolo R, Sangiuolo F, Bombieri C, Bonizzato A, Cardillo G, Raia V, D'apice M, Bettin M, Pignatti P, Castaldo G. Epidemiology and a novel procedure for large scale analysis of CFTR rearrangements in classic and atypical CF patients: a multicentric Italian study. J Cyst Fibros. 2008;7(5):347–351. PubMed

Ramos MD, Masvidal L, Giménez J, Bieth E, Seia M, Georges MD, Armengol L, Casals T. CFTR rearrangements in Spanish cystic fibrosis patients: first new duplication (35kb) characterised in the Mediterranean countries. Ann Hum Genet. 2010;74(5):463–469. PubMed

Taulan M, Viart V, Theze C, Guittard C, Altieri J, Templin C, Mely L, Claustres M, Des Georges M. Identification of a novel duplication CFTRdup2 and functional impact of large rearrangements identified in the CFTR gene. Gene. 2012;500(2):194–198. PubMed

Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M. Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation. J Pediatr. 2017;181:S4–S15.e1. PubMed

Castellani C, Duff AJ, Bell SC, Heijerman HG, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153–178. PubMed

Shoshani T, Augarten A, Gazit E, Bashan N, Yahav Y, Rivlin Y, Tal A, Seret H, Yaar L, Kerem E. Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am J Hum Genet. 1992;50(1):222–228. PubMed PMC

Farra C, Menassa R, Awwad J, Morel Y, Salameh P, Yazbeck N, Majdalani M, Wakim R, Yunis K, Mroueh S. Mutational spectrum of cystic fibrosis in the Lebanese population. J Cyst Fibros. 2010;9(6):406–410. PubMed

Shahin WA, Mehaney DA, El-Falaki MM. Mutation spectrum of Egyptian children with cystic fibrosis. Springerplus. 2016;5(1):1–6. PubMed PMC

Messaoud T, Bibi A, Elion J, Ferec C, Fattoum S. Molecular epidemiology of cystic fibrosis in Tunisia. Ann Biol Clin (Paris) 2005;63(6):627–630. PubMed

Chamayou S, Sicali M, Lombardo D, Maglia E, Liprino A, Cardea C, Fichera M, Venti E, Guglielmino A. The true panel of cystic fibrosis mutations in the Sicilian population. BMC Med Genet. 2020;21(1):1–6. PubMed PMC

des Georges M, Guittard C, Altiéri J, Templin C, Sarles J, Sarda P, Claustres M. High heterogeneity of CFTR mutations and unexpected low incidence of cystic fibrosis in the Mediterranean France. J Cyst Fibros. 2004;3(4):265–272. PubMed

Kanavakis E, Efthymiadou A, Strofalis S, Doudounakis S, Traeger-Synodinos J, Tzetis M. Cystic fibrosis in Greece: molecular diagnosis, haplotypes, prenatal diagnosis and carrier identification amongst high-risk individuals. Clin Genet. 2003;63(5):400–409. PubMed

Deltas CC, Boteva K, Georgiou A, Papageorgiou E, Georgiou C. Description of a symptomless cystic fibrosis L346P/M348K compound heterozygous Cypriot individual. Mol Cell Probes. 1996;10(4):315–318. PubMed